DSM-Firmenich Resultados de beneficios anteriores
Pasado controles de criterios 1/6
DSM-Firmenich's earnings have been declining at an average annual rate of -20.7%, while the Chemicals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 0.8% per year. DSM-Firmenich's return on equity is 4.4%, and it has net margins of 5.4%.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de la industria Chemicals | n/a |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera | n/a |
| Margen neto | n/a |
| Actualización beneficios | n/a |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero DSM-Firmenich. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|
Ingresos de calidad: DSM2 has high quality earnings.
Margen de beneficios creciente: DSM2's current net profit margins (5.4%) are lower than last year (11.3%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: DSM2's earnings have declined by 20.7% per year over the past 5 years.
Acelerando crecimiento: DSM2's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Beneficios vs. Industria: DSM2 had negative earnings growth (-44.6%) over the past year, making it difficult to compare to the Chemicals industry average (-12.3%).
Rentabilidad financiera
Alta ROE: DSM2's Return on Equity (4.4%) is considered low.